A Matching-Adjusted Indirect Comparison of Acalabrutinib vs. Zanubrutinib in Relapsed or Refractory CLL

The Bottom Line:

Acalabrutinib and zanubrutinib have similar excellent efficacy in relapsed or refractory chronic lymphocytic leukemia (CLL). However, acalabrutinib had a lower rate of serious hemorrhage, hypertension, and the need for dose reduction due to adverse events compared to zanubrutinib.

Who Performed the Research and Where Was it Presented:

Dr. Adam Kittai of Ohio State University led a group of international researchers who presented the result of the comparison between acalabrutinib and zanubrutinib at the American Society of Clinical Oncology (ASCO) annual meeting in 2023 in Chicago.

Background:

BTK Inhibitors (BTKi) have revolutionized the treatment of CLL. All three approved BTKi have similar impressive efficacy, ...